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Abstract
Objective: To investigate the association between semaphorin 3A (SEMA 3A) and its receptor neuropilin 1 (NRP1) 
and the clinicopathologic characteristics of patients with tongue cancer. 
Study Design: Forty-three tongue squamous cell carcinoma specimens were included. Immunohistochemical 
staining of SEMA3A and NRP1 was performed on 15 normal tongue epithelium specimens and the 43 tumour 
specimens. Immunoreactivity was evaluated based on the staining intensity and distribution score. Statistical 
analyses were performed using Chi-squared and Spearman tests and Kaplan-Meier analysis. 
Results: SEMA3A was significantly down-regulated in tongue cancer compared with normal tongue (P=0.025), 
while NRP1 was over-expressed in tumours (P<0.001). SEMA3A expression inversely correlated with nodal me-
tastasis (P=0.017). NRP1 expression did not correlate with any clinicopathological characteristics. Higher SE-
MA3A expression strongly predicted longer survival (P=0.005). Scores for the NRP1/SEMA3A ratio of ≥1 pre-
dicted shorter survival (P=0.045). 
Conclusions: Aberrant expression of SEMA3A and its receptor NRP1 might be involved in the development of 
tongue cancer and might be useful prognostic markers in this tumour type. 
Key words: Semaphorin 3A, neuropilin 1, tongue, squamous cell carcinoma.
 
Song X, Zhang W, Zhang Y, Zhang H, Fu Z, Ye J, Liu L, Song X, Wu Y. 
Expression of semaphorin 3A and neuropilin 1 with clinicopathological 
features and survival in human tongue cancer. Med Oral Patol Oral Cir 
Bucal. 2012 Nov 1;17 (6):e962-8.   
 http://www.medicinaoral.com/medoralfree01/v17i6/medoralv17i6p962.pdf
Article Number: 18168         http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.18168
http://dx.doi.org/doi:10.4317/medoral.18168
Introduction
Tongue squamous cell carcinoma has been the leading 
type of oral cancer with the notorious features of early 
lymph node metastasis and poor survival. Although 
treatment, which includes surgery, chemotherapy and 
(or) radiotherapy, has been effective, long-term survival 
has not substantially improved (1-4).
Recently, a growing emphasis has been placed on the 
relationship between the nervous system and cancer 
because increasing evidence supports common genetic 
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mechanisms involved in both cancer development and 
the progression of neurodegenerative disease (5). In-
terestingly, the nervous system might exert a potential 
influence on the development of cancer; environmental 
enrichment (EE) has been shown to significantly inhibit 
xenograft tumour growth, but the mechanism remains 
elusive (6).
Members of the semaphorin (SEMA) family, which 
were originally described as axon guidance molecules 
(7,8), have recently attracted increased attention by on-
cologists because of their roles in tumour growth and 
metastasis (9-13). SEMAs are secreted or membrane-
bound proteins that can be classified into eight classes 
(sema1-sema7 and viral sema). Class 3 semaphorins 
(SEMA3) are the only secreted semaphorins in verte-
brates. Through binding to their receptors, neuropilins 
(NRPs) and plexins, SEMAs may function as chemo-
repellents or chemoattractants (7,8). In addition, other 
molecules can also interact with SEMAs or their recep-
tors on the cell membrane, making it even more difficult 
to predict the exact function of a SEMA. For example, 
SEMA3B, SEMA3F, and SEMA4D have been shown to 
regulate tumour angiogenesis, growth and metastasisin 
different manners (14-16). 
SEMA3A is considered to be a candidate tumour sup-
pressor in some cancers. SEMA3A can inhibit the 
proliferation of malignant mesothelial cells, decrease 
the adhesion or migration of prostate or breast cancer 
cells, and promote apoptosis in leukemic T cells (17,18). 
However, the role of SEMA3A in tongue squamous cell 
carcinoma remains unclear. Therefore, we focused on 
the expression of SEMA3A and its receptor NRP1 in 
tongue cancer and the potential contribution of these 
molecules in the prediction of prognosis. 
Material and Methods
-Patients and tissue samples
Forty-three primary tongue squamous cell carcinoma 
biopsy specimens from patients diagnosed between 
2000 and 2006 were obtained from the Department of 
Oral Pathology and the Department of Oral Maxillo-
facial Surgery in the Stomatologic Hospital of Jiangsu 
Province, Nanjing Medical University. None of the pa-
tients had received any form of tumour-specific therapy 
before surgery. The follow-up period ranged from 2 to 
135 months with an average of 55.6 months and a me-
dian of 70 months. The end point in the analysis was 
carcinoma-related death. Among the 15 normal tongue 
mucosa, 5 were obtained from freshly injured tongue 
mucosa after trauma and 10 were obtained from the de-
fect border after removal of a benign tongue tumour. 
All tissues were obtained with the consent of the pa-
tients. This study protocol was approved by the Ethics 
Committee (Institutional Review Board) of the Nanjing 
Medical University. We have read the Helsinki Declara-
tion and have followed its guidelines in this investiga-
tion.
-Immunohistochemistry 
All specimens were fixed in 10% formaldehyde solution 
and embedded in paraffin. Each tissue section (4-5 um) 
from representative paraffin blocks was deparaffinised 
in xylene and rehydrated through an alcohol gradient. 
Endogenous peroxidases were blocked with 3% hydro-
gen peroxide. For antigen retrieval, the sections were 
processed by conventional microwave heating in 0.01 
M sodium citrate retrieval buffer (pH 6.0) for 20 min. 
The sections were then incubated with a rabbit mono-
clonal Neuropilin primary antibody (1:100; Abcam, 
Cambridge, UK) or a rabbit polyclonal Semaphorin 
3A primary antibody (1:100; Abcam, Cambridge, UK) 
overnight at 4°C and subsequently incubated with goat 
anti-rabbit second antibody (1:5000; Abcam, Cam-
bridge, UK) for 30 min at room temperature. The sec-
tions were then washed three times with Phosphate-
buffered Saline (PBS) (pH 7.2) for 3 min. The reaction 
product was developed with DAB and counterstained 
with haematoxylin. Immunoreactivity in the tissue was 
judged by the pathologist, who was blinded to the clini-
cal data and other immunohistochemical results accord-
ing to the revised criteria suggested by the World Health 
Organization.
-Evaluation of Immunoreactivity 
Immunoreactivity was semi-quantitatively evaluated 
using the staining intensity score and distribution score 
(19). The immunoreactive score was defined as the 
proportion score multiplied by the intensity score. The 
proportion score was defined as 0, negative; 1, <10%; 
2, 11–50%; 3, 51–80%; or 4, >80% positive cells. The 
intensity score was defined as 0, negative; 1, weak; 2, 
moderate; or 3, strong. The total score ranged from 0 to 
12. The immunoreactivity scores were divided into one 
of the following three groups based on the final score; 
negative immunoreactivity was defined as a total score 
of 0, low expression was defined as a total score of 1–4, 
and high expression was defined as a total score of >4. 
-Statistical Analyses
Statistical analyses to compare two groups of data were 
performed using an unpaired Student’s t-test. Ratio 
analysis was performed with a chi-squared or Fisher’s 
exact test. The Spearman test was used in the correla-
tion analysis. Overall survival was obtained using the 
Kaplan-Meier method and compared using the log-rank 
test. P-values less than 0.05 were considered statisti-
cally significant.
Results
-Expression of SEMA3A and NRP1 in tongue squa-
mous cell carcinoma
The immunohistochemical staining results for SE-
MA3A and NRP1 are presented in tables 1,2.
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SEMA3A: SEMA3A was detected primarily in the nu-
cleus and cytoplasm of the normal squamous tongue 
epithelium with moderate to strong immunoreactivity 
(Fig. 1A), especially in basal membrane cells. Only 2 
(13.3%) of the 15 normal tongue epithelium specimens 
showed negative staining (Table 1). However, among the 
43 tongue squamous cell carcinomas, negative staining 
was observed in 18 specimens (41.9%), high expres-
sion was observed in 8 (18.6%), and low expression was 
observed in 17 (39.5%). A significant difference in the 
expression of SEMA3A existed between normal and tu-
mour tissues (P=0.025) (Table 1). 
NRP1: Among the 15 normal tongue epithelium tis-
sues, only 3 (20%) showed positive NRP1 expression 
(Fig. 1B), while positive staining was observed in 38/43 
(88.3%) tumour specimens. Among the tumour speci-
mens, 25/43 (58.15%) displayed low expression and 
13/43 (30.2%) displayed high expression. The NRP1 
expression, which was observed in the membrane and 
cytoplasm, was located primarily in cancer nests. (Fig. 
2) shows strongly positive NRP1 expression (Fig. 2A) 
and negative SEMA3A expression (Fig. 2B) within the 
same specimen. A significant difference existed be-
tween the expression of NRP1 in normal and tumour 
tissues (P<0.001) (Table 1).
-Association between the expression of SEMA3A and 
NRP1 and clinicopathologic features
The relationship between the expression of SEMA3A 
and NRP1 is shown in table 2. A significant difference 
in SEMA3A expression was observed between the N0 
No.
SEMA3A NRP1 
N L H    P N L H      P 
Tumor 43 18 17 8 0.025 5 25 13 <0.001
Normal 15 2 5 8  12 3 0  
Table 1. Expression of SEMA3A and NRP1 in normal tongue epithelum and 
tongue suqamous cell carcinoma.
No., number of patients; N, negtive; L, low expression; H, high expression.
Characteristic
No. 
SEMA3A NRP1 
N P P N P P
Age (years)  0.941  0.982 
?50 17 7 10  2 15  
>50 26 11 15  3 23  
Sex  0.336  0.928 
Male 25 12 13  3 22  
Female 18 6 12  2 16  
Tumor grade  0.268  0.674 
Well 21 7 14  2 19  
M+P 22 11 11  3 19  
T stage  0.707 0.612 
T1-2 30 12 18  3 27  
T3-4 13 6 7  2 11  
N stage  0.017 0.612 
N0 30 9 21  3 27  
N(+) 13 9 4  2 11  
 
Table 2. Relationship between SEMA3A and NRP1 expression levels of 
the tumors and clinical characteristic.
No., number of patients; N, negative; P, positive; M+P, moderate and 
poor; N(+), nodal metastasis.
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and N(+) groups (P=0.017). Significantly lower expres-
sion of SEMA3A was observed in the lymph node me-
tastasis group. We did not observe any significant dif-
ference in SEMA3A between the groups classified by 
age, sex or tumour T stages. Similarly, no significant 
difference in NRP1 was observed between the groups 
(Table 2).  
-Association between the expression of SEMA3A and 
NRP1 and survival
To the latest follow-up time, 23 of 43 (53.4%) patients 
were alive without recurrence, and 1 (2.3%) patient was 
alive with recurrent disease. The other 19 patients had 
died from recurrent disease. The overall survival of 
the 43 patients is shown in figure 3A. The 1-year and 
5-year overall survival rates were 76.7% and 58.1%, 
respectively. High expression of SEMA3A predicted 
a significantly longer survival than low expression of 
SEMA3A (Fig. 3B). However, the overall survival was 
not observed to be significantly different between the 
patients with high vs. low expression of NRP1 (Fig. 3C). 
Interestingly, although no correlation existed between 
the expression of SEMA3A and NRP1 (Table 3), in 
some patients, NRP1 was strongly positive while SE-
MA3A was almost totally absent (Fig. 2). Therefore, we 
compared the NRP1 and SEMA3A scores. Surprisingly, 
we found that patients with higher scores for the ratio 
of NRP1 to SEMA3A (NRP/SEMA3A ≥1) also showed 
a significantly shorter overall survival than those with 
scores <1 (Fig. 3D).    
Fig. 1. The expression of SEMA3A and NRP1 in normal tongue epithelium. SEMA3A was highly expressed in 
normal tongue epithelium, especially in the basal cell layer A) NRP1 was not expressed in normal epithelium 
B) (×400). 
Fig. 2. Aberrant expression of SEMA3A and NRP1 within the same tongue squamous cell carcinoma speci-
men. SEMA3A expression was negative A), while NRP1 was strongly immunostained B) (×400).
Variable No. 
SEMA3A
P
N   P 
NRP1  0.680 
    N    5      2 3 
    P  38     16 22 
Table 3. Correlation between expression of SE-
MA3A and NRP1 in tongue cancer.
No., number of patients; N, negative; P, positive.
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Discussion
Semaphorins and their receptors are involved in func-
tions other than axonal guidance (20,21). However, 
the roles of SEMA3A and its receptor NRP1 have not 
been extensively studied, particularly in the long-term 
survival of patients with head and neck cancer. In this 
study, we focused on the most common type of oral can-
cer, tongue squamous cell carcinoma, and examined the 
expression of SEMA3A and NRP1. We found that no 
correlation existed between the expression of SEMA3A 
and NRP1 in tongue cancer specimens. However, loss 
of SEMA3A expression was observed in tongue cancer 
compared with normal tongue epithelium. The expres-
sion of the NRP1 receptor was remarkably elevated. 
The discrepant change in SEMA3A signalling in tongue 
cancer in our study indicates the important role of this 
protein in the development of the disease. Moreover, 
lower expression of SEMA3A correlated with poor 
prognosis, suggesting a tumour suppressor function for 
SEMA3A in human tongue cancer. In fact, SEMA3A 
has been implicated as a tumour suppressor in other 
types of cancer (22-24). The mechanism involved in the 
tumour inhibition by SEMA3A might relate to its in-
teraction with integrins. For example, in breast cancer, 
Fig. 3. Analysis of SEMA3A and NRP1 expression and the survival of patients with tongue cancer. A) Overall survival curves of the 43 pa-
tients with tongue squamous cell carcinoma. B) Survival curves of the 43 patients with higher or lower expression of SEMA3A (log-rank test, 
P=0.005). C) Survival curves of the 43 patients with higher or lower expression of NRP1 (log-rank test, P=0.385). D) Survival curves of the 43 
patients with NRP1/SEMA3A score ≥1 or <1 (log-rank test, P=0.045).
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SEMA3A can inhibit cell attachment and cell migration 
by affecting the activation or stabilisation of surface in-
tegrins. Inhibition of integrins by SEMA3A could result 
in a blockade of endothelial and tumour cell migration, 
leading to reduced tumour angiogenesis and metastasis 
(25,26). In our study, we also found that SEMA3A ex-
pression inversely correlated with lymph node metasta-
sis. This result indicates a role for SEMA3A in blocking 
tumour cell migration and metastasis. However, Pan et 
al. (22) have found that through binding to NRP1, SE-
MA3A can also suppress breast tumour cell migration 
by increasing the expression of integrin a2b1 in an au-
tocrine fashion These conflicting results may reflect an 
ability of SEMA3A to differentially impact the adhe-
sion of different cell types. In a more recent study on 
miRNA, Gaziel-Sovran A (27) have observed that miR-
30b/30d upregulation correlates with higher metastatic 
potential, shorter time to recurrence, and reduced over-
all survival. Among the target genes of miR-30b/30d, 
the authors found a significant down-regulation of SE-
MA3A. Together with our results, these data indicate 
that SEMA3A might also be involved in modulating the 
epithelial to mesenchymal transition and metastasis. 
The ability of SEMA3A to inhibit tumour angiogenesis 
by competing with vascular endothelium growth factor 
(VEGF) for binding with NRP1 has been more inten-
sively studied and confirmed. Because VEGF is often 
up-regulated in a majority of malignancies, including 
head neck cancer, SEMA3A signalling might be in-
hibited by the binding of VEGF to NRP1. NRP1 is a 
single transmembrane glycoprotein with a molecular 
weight of approximately 130–140 kDa. NRP1 consists 
of a large extracellular domain, a short transmembrane 
domain and a short cytoplasmic domain. The binding 
domains for SEMA3A and VEGF are located in the ex-
tracellular domain and are named the A and B domains, 
respectively. However, SEMA3A can also bind to the 
B domain, which accounts for some of the observed 
functional competition between VEGF and SEMA3A 
for NRP1 binding (28). NRP1 has been reported to be 
up-regulated in many tumour types, and some clinical 
studies have shown that NRP1 overexpression is posi-
tively associated with metastatic potential, advanced 
stage, and clinical grade in prostate carcinoma, gastroin-
testinal carcinoma and colorectal carcinoma (29-32). In 
our study, NRP1 was poorly expressed in normal oral 
epithelium but was extensively up-regulated in tongue 
cancer tissue. However, this elevation did not correlate 
with any clinicopathologic characteristics, indicating its 
controversial role in tumour growth. The upregulation 
of NRP1 also did not correlate with significantly shorter 
survival. However, when combined with SEMA3A, we 
found that the ratio of NRP1 to SEMA3A also negatively 
correlated with survival. Specimens with higher NRP1 
to SEMA3A expression scores corresponded to shorter 
survival. One explanation for this result may be that 
when NRP1 is expressed at higher levels than needed by 
SEMA3A, NRP1 predicts a worse prognosis. However, 
VEGF should also be taken into account because a bal-
ance between VEGF and SEMA3A is always present, 
and this balance modulates the cellular proliferation or 
apoptosis (33). If this balance is destroyed, SEMA3A of-
ten requires a higher concentration of NRP1 for binding 
than needed by VEGF (34). Therefore, we hypothesised 
that during the development of cancer, especially dur-
ing the angiogenic process, the elevation of VEGF by 
tumour cells functions more than SEMA3A and NRP1 
plays greater roles with VEGF than with SEMA3A. 
Therefore, VEGF and NRP1 expression increases and 
SEMA3A expression decreases. However, NRP1 is also 
involved in many other signalling pathways in addition 
to SEMA3A and VEGF. Therefore, much remains to be 
studied regarding the exact role of NRP1 and the rela-
tionship between the SEMA3s and VEGF in different 
types of cancer. 
In conclusion, in this study, we observed the over-ex-
pression of NRP1 and loss of SEMA3A expression in 
human tongue cancer. Although the elevated expression 
of NRP1 did not correlate with any clinical characteris-
tics in our study (more cases were potentially needed), 
lower expression of SEMA3A was strongly associated 
with worse patient survival. The combination analysis 
of SEMA3A together with NRP1 also provides a novel 
approach for assessing prognosis in this malignancy. 
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